OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Rating of “Buy” by Analysts

OrthoPediatrics Corp. (NASDAQ:KIDSGet Rating) has been given an average recommendation of “Buy” by the seven brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $73.00.

A number of research firms have recently weighed in on KIDS. TheStreet upgraded shares of OrthoPediatrics from a “d+” rating to a “c” rating in a research note on Monday, April 4th. Needham & Company LLC reduced their price target on shares of OrthoPediatrics from $83.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, March 3rd.

In related news, CEO David R. Bailey sold 4,078 shares of the firm’s stock in a transaction that occurred on Wednesday, March 2nd. The shares were sold at an average price of $58.10, for a total value of $236,931.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gregory A. Odle sold 4,108 shares of the firm’s stock in a transaction that occurred on Wednesday, March 2nd. The stock was sold at an average price of $57.55, for a total transaction of $236,415.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,204 shares of company stock valued at $1,482,701. 30.30% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Confluence Wealth Services Inc. bought a new stake in shares of OrthoPediatrics in the 4th quarter valued at $28,000. UBS Group AG grew its position in OrthoPediatrics by 106.4% in the 3rd quarter. UBS Group AG now owns 421 shares of the company’s stock valued at $28,000 after purchasing an additional 217 shares during the period. Sageworth Trust Co of South Dakota acquired a new stake in OrthoPediatrics in the 4th quarter valued at $43,000. Maverick Capital Ltd. acquired a new stake in OrthoPediatrics in the 3rd quarter valued at $73,000. Finally, Advisor Group Holdings Inc. grew its position in OrthoPediatrics by 27.1% in the 3rd quarter. Advisor Group Holdings Inc. now owns 1,524 shares of the company’s stock valued at $99,000 after purchasing an additional 325 shares during the period. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Shares of OrthoPediatrics stock opened at $49.93 on Tuesday. The firm has a market capitalization of $1.01 billion, a P/E ratio of -59.44 and a beta of 0.79. OrthoPediatrics has a 12-month low of $43.09 and a 12-month high of $73.91. The business’s 50-day moving average price is $51.93.

OrthoPediatrics (NASDAQ:KIDSGet Rating) last announced its quarterly earnings data on Wednesday, March 2nd. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.05. OrthoPediatrics had a negative net margin of 16.58% and a negative return on equity of 6.54%. During the same quarter in the prior year, the business earned ($0.31) EPS. On average, analysts expect that OrthoPediatrics will post -0.62 earnings per share for the current year.

About OrthoPediatrics (Get Rating)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

Featured Stories

Analyst Recommendations for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.